Advertisement

Evaluation of long-term treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies

      Abstract

      Objective: Evaluation of the benefit/risk ratio of long-term treatment with indomethacin in salt-losing tubulopathies with special attention to renal function. Study design: Twelve patients (median age, 14.9 years) had received indomethacin for a median of 13 years (median cumulative dose, 10.7 g/kg). Creatinine clearance, serum electrolyte levels, endocrine status, and excretion of prostaglandins and electrolytes were examined during indomethacin therapy and after its withdrawal. All patients underwent ultrasound-guided renal biopsy. For statistical evaluation, the Wilcoxon test and Pearson correlation coefficient were used. Results: After indomethacin withdrawal, the biochemical features of the tubulopathy reappeared. The median creatinine clearance rose from 67.4 to 96.5 mL/min/1.73 m2 (P < .05) but remained subnormal in 4 patients. Ultrasonography elucidated medullary nephrocalcinosis in 8 patients. Renal tissue showed slight/moderate focal tubular atrophy and interstitial fibrosis in 8 patients. Comparison with biopsy specimens, obtained 11 to 14 years before study participation from 5 patients, revealed no progression. A correlation between fractional sodium and magnesium excretion and percentage of altered tubulointerstitial compartment was found (P < .001). The 4 patients with mutations in the gene of the inwardly rectifying adenosine triphosphate–regulated potassium channel (ROMK) had almost normal renal histologic findings and normal renal function. Conclusion: Renal function and histology are unaffected by long-term indomethacin treatment. (J Pediatr 2001;139:398-406)

      Abbreviations:

      cBS (Classic Bartter's syndrome), CLC-Kb (Chloride channel kidney b), FE (Fractional excretion), GFR (Glomerular filtration rate), HPS/aBS (Hyperprostaglandin E syndrome/antenatal Bartter's syndrome), NKCC2 (Furosemide-sensitive sodium-potassium–2 chloride cotransporter), NSAID (Nonsteroidal anti-inflammatory drug), PGE (Prostaglandin E), ROMK (Inwardly rectifying adenosine triphosphate–regulated potassium channel)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Pediatrics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Simon DB
        • Karet FE
        • Hamdan JM
        • Di Pietro A
        • Sanjad SA
        • Lifton RP
        Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2.
        Nat Genet. 1996; 13: 183-188
        • Simon DB
        • Karet FE
        • Rodriguez-Soriano J
        • Hamdan JH
        • DiPietro A
        • Trachtman H
        • et al.
        Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK.
        Nat Genet. 1996; 14: 152-156
        • Károlyi L
        • Konrad M
        • Köckerling A
        • Ziegler A
        • Zimmermann DK
        • Roth B
        • et al.
        Mutations in the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome: evidence for genetic heterogeneity.
        Hum Mol Gen. 1997; 6: 17-26
        • Simon DB
        • Bindra RS
        • Mansfield TA
        • Nelson-Williams C
        • Mendonca E
        • Stone R
        • et al.
        Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III.
        Nat Genet. 1997; 17: 171-178
        • Konrad M
        • Vollmer M
        • Lemmink H
        • van der Heuvel B
        • Jeck N
        • Vargas-Poussou R
        • et al.
        Mutations in the chloride channel gene, CLCNKB as a cause of Bartter syndrome.
        J Am Soc Nephrol. 2000; 11: 1449-1459
        • Simon DB
        • Nelson-Williams C
        • Johnson Bia M
        • Ellison D
        • Karet FE
        • Morey Molina A
        • et al.
        Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl-cotransporter.
        Nat Genet. 1996; 12: 24-30
        • Seyberth HW
        • Rascher W
        • Schweer H
        • Kühl PG
        • Mehls O
        • Schärer K
        Congenital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome.
        J Pediatr. 1985; 107: 694-701
        • Verberckmoes R
        • van Damme B
        • Clement J
        • Amery A
        • Michielsen P
        Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin.
        Kidney Int. 1976; 9: 302-307
        • Seidel C
        • Reinalter S
        • Seyberth HW
        • Schärer K
        Prepubertal growth in the hyperprostaglandin E syndrome.
        Pediatr Nephrol. 1995; 9: 723-728
        • Leonhardt A
        • Timmermanns G
        • Roth B
        • Seyberth HW
        Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome.
        J Pediatr. 1992; 120: 546-554
        • Konrad M
        • Leonhardt A
        • Hensen P
        • Seyberth HW
        • Köckerling A
        Prenatal and postnatal management of hyperprostaglandin E syndrome after genetic diagnosis from amniocytes.
        Pediatrics. 1998; 103: 678-683
        • Bartter FC
        • Pronove P
        • Gill JR
        • MacCardle RC
        • Diller E
        Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis—a new syndrome.
        Am J Med. 1962; 33: 811-828
        • Taugner R
        • Waldherr R
        • Seyberth HW
        • Erdös EG
        • Menard J
        • Schneider D
        The juxtaglomerular apparatus in Bartter's syndrome and related tubulopathies: an immunocytochemical and electron microscopic study.
        Virch Arch Pathol Anat Histopathol. 1988; 412: 459-470
        • Schwartz ID
        • Alon US
        Bartter syndrome revisited.
        J Nephrol. 1996; 9: 81-87
        • Arant BS
        • Brackett NC
        • Young RB
        • Still WJS
        Case study of siblings with juxtaglomerular hyperplasia and secondary aldosteronism associated with severe azotemia and renal rickets—a Bartter's syndrome or disease?.
        Pediatrics. 1970; 46: 344-361
        • Pierratos A
        • Couture RA
        • Hierlihy PJ
        • Bell RC
        • Levine DZ
        Bartter's syndrome, nephrocalcinosis and renal insufficiency.
        CMAJ. 1989; 141: 1055-1057
        • Takahashi M
        • Yanagida N
        • Okano M
        • Ishizaki A
        • Megurao J
        • Kukita K
        • et al.
        A first report: living related kidney transplantation on a patient with Bartter's syndrome.
        Transplant Proc. 1996; 28: 1588
        • Fanconi A
        • Schachenmann G
        • Nüssli R
        • Prader A
        Chronic hypokalaemia with growth retardation, normotensive hyperrenin-hyperaldosteronism (“Bartter's syndrome”), and hypercalciuria.
        Helv Paediatr Acta. 1971; 2: 144-163
        • Jeck ND
        • Konrad M
        • Reinalter S
        • Marg W
        • Morlot M
        • Filler G
        • et al.
        Hypokalemic salt losing tubulopathy with associated hearing loss [abstract].
        Pediatr Res. 2000; 47: 447A
        • Sato K
        • Ogata M
        A patient with chronic renal failure due to Bartter's syndrome [abstract].
        Jpn J Nephrol. 1995; 37: 404-409
        • Lindsley CB
        • Warady BA
        Nonsteroidal anti-inflammatory drugs: renal toxicity. Review of pediatric issues.
        Clin Pediatr. 1990; 29: 10-13
        • Perneger TV
        • Whelton PK
        • Klag MJ
        Risk of kidney failure associated with the use of acetaminophen, aspirin and nonsteroidal anti-inflammatory drugs.
        N Engl J Med. 1994; 331: 1675-1679
        • Henrich WL
        • Agodoa LE
        • Barrett B
        • Bennett WM
        • Blantz RC
        • Buckalew Jr, VM
        • et al.
        National Kidney Foundation Position Paper: Analgesics and the kidney: Summary and recommendations to the scientific advisory board of the National Kidney Foundation from an ad hoc Committee of the National Kidney Foundation.
        Am J Kidney Dis. 1996; 27: 162-165
        • Molzahn M
        • Pommer W
        • De Broe ME
        • Elseviers MM
        Analgesic nephropathy.
        in: 2nd ed. Oxford textbook of clinical nephrology. : Oxford Medical Publications, New York1998: 1129-1146
        • Conn JW
        • Johnson RD
        Kaliopenic nephropathy.
        Am J Clin Nutr. 1956; 4: 523-528
        • Potter WZ
        • Trygstad CW
        • Helmer OM
        • Nance WE
        • Judson WE
        Familial hypokalemia associated with renal interstitial fibrosis.
        Am J Med. 1974; 57: 971-977
        • Cremer W
        • Bock KD
        Symptoms and course of chronic hypokalemic nephropathy in man.
        Clin Nephrol. 1977; 7: 112-117
        • Riemenschneider T
        • Bohle A
        Morphologic aspects of low-potassium and low-sodium nephropathy.
        Clin Nephrol. 1983; 19: 271-279
        • Wrong O
        Nephrocalcinosis.
        in: 2nd ed. Oxford textbook of clinical nephrology. : Oxford Medical Publications, New York1998: 1375-1396
        • Seyberth HW
        • Soergel M
        • Köckerling A
        Hypokalemic tubular disorders: the hyperprostaglandin E syndrome and the Bartter-Gitelman syndrome.
        in: 2nd ed. Oxford textbook of clinical nephrology. : Oxford Medical Publications, New York1998: 1085-1093
        • Schröter J
        • Timmermanns G
        • Seyberth HW
        • Greven J
        • Bachmann S
        Marked reduction of Tamm-Horsfall protein synthesis in hyperprostaglandin E syndrome.
        Kidney Int. 1993; 44: 401-410
        • Köckerling A
        • Reinalter SC
        • Seyberth HW
        Impaired response to furosemide in hyperprostaglandin E syndrome: evidence for a tubular defect in the loop of Henle.
        J Pediatr. 1996; 129: 519-528
        • Rane A
        • Oelz O
        • Frölich JC
        • Seyberth HW
        • Sweerman BJ
        • Watson JT
        • et al.
        Relation between plasma concentration of indomethacin and its effects on prostaglandin synthesis and platelet aggregation in man.
        Clin Pharmacol Ther. 1978; 23: 658-668
        • Patriquin H
        • Robitaille P
        Renal calcium deposition in children: sonographic demonstration of the Anderson-Carr progression.
        AJR Am J Roentgenol. 1986; 146: 1253-1256
        • Skellern GG
        • Salole EG
        High-speed liquid chromatographic analysis of indomethacin in plasma.
        J Chromatogr. 1975; 114: 483-485
        • Schweer H
        • Watzer B
        • Seyberth HW
        Determination of 7 prostaniods in 1 ml of urine by gas chromatography-negative ion chemical ionization triple stage quatropole mass spectrometry.
        J Chromatogr B. 1994; 652: 221-227
        • Seyberth HW
        • Sweetman BJ
        • Frölich JC
        • Oates JA
        Quantification of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies.
        Prostaglandins. 1976; 11: 381-397
        • McCrory W
        Developmental nephrology.
        in: 15th ed. Nelson textbook of pediatrics. : Saunders Company, Philadelphia1996: 1482
        • Landau D
        • Shalev H
        • Ohaly M
        • Carmi R
        Infantile variant of Bartter syndrome and sensorineural deafness: a new autosomal recessive disorder.
        Am J Med Genet. 1995; 59: 454-459